WO2012169785A3 - Symmetrically structured quinazoline derivatives - Google Patents
Symmetrically structured quinazoline derivatives Download PDFInfo
- Publication number
- WO2012169785A3 WO2012169785A3 PCT/KR2012/004475 KR2012004475W WO2012169785A3 WO 2012169785 A3 WO2012169785 A3 WO 2012169785A3 KR 2012004475 W KR2012004475 W KR 2012004475W WO 2012169785 A3 WO2012169785 A3 WO 2012169785A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quinazoline derivatives
- symmetrically structured
- structured
- symmetrically
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a novel quinazoline derivative and a pharmaceutical composition for preventing or treating cancers, inflammatory diseases, autoimmune diseases, or neurodegenerative disorders comprising same as an active ingredient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0054581 | 2011-06-07 | ||
KR1020110054581A KR20120135716A (en) | 2011-06-07 | 2011-06-07 | Symmetrically structured quinazoline derivative compounds and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2012169785A2 WO2012169785A2 (en) | 2012-12-13 |
WO2012169785A3 true WO2012169785A3 (en) | 2013-03-28 |
WO2012169785A9 WO2012169785A9 (en) | 2013-05-23 |
Family
ID=47296590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/004475 WO2012169785A2 (en) | 2011-06-07 | 2012-06-07 | Symmetrically structured quinazoline derivatives |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20120135716A (en) |
WO (1) | WO2012169785A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061283B (en) * | 2015-08-09 | 2017-11-24 | 浙江大学 | The preparation method of amino-acid benzyl ester hydrochloride |
WO2019023275A1 (en) * | 2017-07-25 | 2019-01-31 | Hepagene Therapeutics, Inc. | Dimeric peptide inhibitors of apoptosis proteins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
US20080027084A1 (en) * | 2006-07-28 | 2008-01-31 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity crystalline forms and process |
-
2011
- 2011-06-07 KR KR1020110054581A patent/KR20120135716A/en not_active Application Discontinuation
-
2012
- 2012-06-07 WO PCT/KR2012/004475 patent/WO2012169785A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
US20080027084A1 (en) * | 2006-07-28 | 2008-01-31 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity crystalline forms and process |
Also Published As
Publication number | Publication date |
---|---|
KR20120135716A (en) | 2012-12-17 |
WO2012169785A2 (en) | 2012-12-13 |
WO2012169785A9 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012104655A3 (en) | Compostions and methods for treating chronic inflammation and inflammatory diseases | |
EP3040072A4 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
WO2013012915A8 (en) | Heterocyclic compounds and uses thereof | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
WO2013134047A3 (en) | Aminoquinoline derivatives and uses thereof | |
WO2012174158A3 (en) | Administration of benzodiazepine | |
WO2012125544A3 (en) | Necroptosis inhibitors and methods of use therefor | |
WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
WO2011141488A3 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2013150529A3 (en) | Indole, indoline derivatives, compositions comprising them and uses thereof | |
WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
MX363530B (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof. | |
WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
WO2014100735A3 (en) | Diazole amides | |
WO2013100718A3 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient | |
WO2015082590A3 (en) | Bis-mmf derivatives | |
WO2014105777A8 (en) | Cobicostat dichlohydrate salt | |
WO2014145126A3 (en) | Methods of treating dyskinesia and related disorders | |
WO2012169785A3 (en) | Symmetrically structured quinazoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12796519 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12796519 Country of ref document: EP Kind code of ref document: A2 |